Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- FDA Approves 2-Month Long-Acting Abilify: Otsuka/Lundbeck
May 1, 2023
- Takeda Files TAK-662 for Congenital Protein C Deficiency in Japan
May 1, 2023
- Astellas Logs 17.2% Sales Growth in FY2022 on Xtandi, but Profits Fall
April 28, 2023
- Daiichi Sankyo on Path to Net 2 Trillion Yen in Sales by FY2025 on Robust Core Products
April 28, 2023
- Chugai’s Q1 Profit Drops by Half in Pullback from Alexion Settlement Gain
April 28, 2023
- Astellas to Promote HR Chief Katsuyoshi Sugita to EVP
April 28, 2023
- Taiho’s Futibatinib Nabs EU Panel Backing for Bile Duct Cancer
April 28, 2023
- Chugai Seeks Vabysmo Label Expansion for RVO
April 28, 2023
- 374 Chugai Employees Apply for Voluntary Redundancy Program
April 28, 2023
- Global PIII Launched for Novel β-Lactamase Inhibitor Nacubactam: Meiji
April 27, 2023
- Pfizer Japan Files Combo Antibiotic Containing β-Lactamase Inhibitor
April 27, 2023
- Stelues Data in Japanese to Be Gathered via Normal Pharmacovigilance Activities: Pfizer
April 27, 2023
- Pfizer Japan Files Genotropin for Prader-Willi Syndrome
April 26, 2023
- HUYA’s Hiyasta Enters PIII Melanoma Study in Japan: Meiji
April 26, 2023
- Lilly Japan Suffers Negative Growth for 3rd Straight Year in 2022 as 2 Major LOEs Weigh
April 26, 2023
- Sumitomo Curbs Shipments of Diabetes Hopeful Twymeeg on More-Than-Expected Demands
April 25, 2023
- Santen to Forge Ahead with Structure Reform, Revenue Revamp to Upscale Growth
April 25, 2023
- Actemra Approved in Taiwan for Hospitalized COVID-19 Patients: Chugai
April 25, 2023
- Takeda Installs Chief Tech Officer Role as It Revs Up Digital Drive: CEO
April 24, 2023
- Mitsubishi Sent Letter Agreeing to Call Off Muse Cell License Deal: Researchers
April 24, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…